| hERG1 channels modulate integrin signaling to trigger angiogenesis and tumor progression in colorectal cancer O Crociani, F Zanieri, S Pillozzi, E Lastraioli, M Stefanini, A Fiore, ... Scientific reports 3 (1), 3308, 2013 | 105 | 2013 |
| Potassium channels: novel emerging biomarkers and targets for therapy in cancer M D'Amico, L Gasparoli, A Arcangeli Recent patents on anti-cancer drug discovery 8 (1), 53-65, 2013 | 79 | 2013 |
| The combined activation of KCa3. 1 and inhibition of Kv11. 1/hERG1 currents contribute to overcome Cisplatin resistance in colorectal cancer cells S Pillozzi, M D'Amico, G Bartoli, L Gasparoli, G Petroni, O Crociani, ... British journal of cancer 118 (2), 200-212, 2018 | 72 | 2018 |
| The conformational state of hERG1 channels determines integrin association, downstream signaling, and cancer progression A Becchetti, S Crescioli, F Zanieri, G Petroni, R Mercatelli, S Coppola, ... Science signaling 10 (473), eaaf3236, 2017 | 61 | 2017 |
| NAMI-A is highly cytotoxic toward leukaemia cell lines: Evidence of inhibition of KCa 3.1 channels S Pillozzi, L Gasparoli, M Stefanini, M Ristori, M D'Amico, E Alessio, ... Dalton Transactions 43 (32), 12150-12155, 2014 | 53 | 2014 |
| Stromal cell protein kinase C-β inhibition enhances chemosensitivity in B cell malignancies and overcomes drug resistance E Park, J Chen, A Moore, M Mangolini, A Santoro, JR Boyd, H Schjerven, ... Science translational medicine 12 (526), eaax9340, 2020 | 30 | 2020 |
| New pyrimido-indole compound CD-160130 preferentially inhibits the KV11. 1B isoform and produces antileukemic effects without cardiotoxicity L Gasparoli, M D’Amico, M Masselli, S Pillozzi, R Caves, R Khuwaileh, ... Molecular Pharmacology 87 (2), 183-196, 2015 | 30 | 2015 |
| The AAA+ ATPase RUVBL2 is essential for the oncogenic function of c-MYB in acute myeloid leukemia E Armenteros-Monterroso, L Zhao, L Gasparoli, T Brooks, K Pearce, ... Leukemia 33 (12), 2817-2829, 2019 | 21 | 2019 |
| Macrolide antibiotics exert antileukemic effects by modulating the autophagic flux through inhibition of hERG1 potassium channels S Pillozzi, M Masselli, L Gasparoli, M D'amico, L Polletta, M Veltroni, ... Blood Cancer Journal 6 (5), e423, 2016 | 16 | 2016 |
| Identification of a c-MYB-directed therapeutic for acute myeloid leukemia K Clesham, V Walf-Vorderwülbecke, L Gasparoli, C Virely, S Cantilena, ... Leukemia 36 (6), 1541-1549, 2022 | 13 | 2022 |
| Direct targeted therapy for MLL‐fusion‐driven high‐risk acute leukaemias S Cantilena, L Gasparoli, D Pal, O Heidenreich, JH Klusmann, ... Clinical and Translational Medicine 12 (6), e933, 2022 | 8 | 2022 |
| An analytical method for the quantification of hERG1 channel gene expression in human colorectal cancer A Fortunato, L Gasparoli, S Falsini, B Luca, A Arcangeli Diagnostic Molecular Pathology 22 (4), 215-221, 2013 | 5 | 2013 |
| ARHGEF4 Regulates an Essential Oncogenic Program in t (12; 21)-Associated Acute Lymphoblastic Leukemia C Virely, L Gasparoli, M Mangolini, K Clesham, S Inglott, D Edwards, ... HemaSphere 4 (5), e467, 2020 | 1 | 2020 |
| Targeting ARHGEF4 in cancer M Mangolini, L Gasparoli, C Virely, D Edwards, J Bartram, N Goulden, ... Klinische Pädiatrie 229 (03), A5, 2017 | 1 | 2017 |
| Aberrant transcriptional pathways in t(12;21) Acute Lymphoblastic Leukemia A Sundaresh, L Gasparoli, M Mangolini, D Edwards, M Hubank, T Brooks, ... Klinische Padiatrie 228 (A12), 2016 | 1 | 2016 |
| Susceptibility of pediatric acute lymphoblastic leukemia to STAT3 inhibition depends on p53 induction L Gasparoli, C Virely, A Tsakaneli, N Che, D Edwards, J Bartram, ... Haematologica 109 (4), 1069, 2024 | | 2024 |
| Establishing the mechanism for RUVBL2 essentiality in acute myeloid leukaemia C Virely, E Armenteros-Monterroso, L Gasparoli, JHA Martens, ... Klinische Pädiatrie 234 (03), 0011, 2022 | | 2022 |
| Deciphering STAT3 dependency in paediatric acute lymphoblastic leukemia L Gasparoli, C Virely, S Cantilena, J Bartram, S Inglott, J De Boer, ... Klinische Pädiatrie 232 (03), 2020 | | 2020 |
| Targeting c-MYB in Acute Leukaemia through Drug Repositioning KJ Clesham, L Gasparoli, C Virely, S Cantilena, J De Boer, O Williams Klinische Pädiatrie 231 (03), 38, 2019 | | 2019 |
| hERG1 channel as a molecular target for new anticancer therapeutic approaches L Gasparoli | | 2014 |
Andrea BecchettiUniversity of Milano-BicoccaVerified email at unimib.it
